ATE106013T1 - Arzneimittelfreisetzungssystem aus glucan und adjuvant. - Google Patents

Arzneimittelfreisetzungssystem aus glucan und adjuvant.

Info

Publication number
ATE106013T1
ATE106013T1 AT90910219T AT90910219T ATE106013T1 AT E106013 T1 ATE106013 T1 AT E106013T1 AT 90910219 T AT90910219 T AT 90910219T AT 90910219 T AT90910219 T AT 90910219T AT E106013 T1 ATE106013 T1 AT E106013T1
Authority
AT
Austria
Prior art keywords
glucan
drug
pct
drug delivery
beta
Prior art date
Application number
AT90910219T
Other languages
English (en)
Inventor
Spiros Jamas
Gary R Ostroff
D Davidson Easson Jr
Original Assignee
Alpha Beta Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha Beta Technology filed Critical Alpha Beta Technology
Application granted granted Critical
Publication of ATE106013T1 publication Critical patent/ATE106013T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/817—Entrapped within the carrier, e.g. gel, hollow fibre

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT90910219T 1989-06-15 1990-06-14 Arzneimittelfreisetzungssystem aus glucan und adjuvant. ATE106013T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/366,490 US5032401A (en) 1989-06-15 1989-06-15 Glucan drug delivery system and adjuvant

Publications (1)

Publication Number Publication Date
ATE106013T1 true ATE106013T1 (de) 1994-06-15

Family

ID=23443232

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90910219T ATE106013T1 (de) 1989-06-15 1990-06-14 Arzneimittelfreisetzungssystem aus glucan und adjuvant.

Country Status (9)

Country Link
US (3) US5032401A (de)
EP (1) EP0476063B1 (de)
JP (1) JPH05503285A (de)
AT (1) ATE106013T1 (de)
AU (1) AU5933190A (de)
CA (1) CA2059275A1 (de)
DE (1) DE69009185T2 (de)
ES (1) ES2053198T3 (de)
WO (1) WO1990015596A1 (de)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
CA2066172A1 (en) * 1989-09-08 1991-03-09 Alpha Beta Technology, Inc. Method for producing soluble glucans
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
FR2655267B1 (fr) * 1989-12-04 1992-04-03 Roussel Uclaf Nouveau derive sulfate du galactanne extrait de klebsiella, procede de preparation, application a titre de medicaments et compositions pharmaceutiques le renfermant.
JPH0665649B2 (ja) * 1991-02-01 1994-08-24 台糖株式会社 甲殻類の生体防御能増強剤、感染症予防ワクチン及び飼料
FR2674755B1 (fr) * 1991-04-05 1995-02-03 Thorel Jean Noel Nouvelles compositions medicamenteuses immunostimulatrices.
JP3522772B2 (ja) * 1991-05-21 2004-04-26 台糖株式会社 ワクチンの免疫効果増強剤
IL104382A0 (en) * 1992-01-17 1993-05-13 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant
EP0640348A1 (de) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Adjuvansmischung auf Ölbasis und auf Wasserbasis
JP3320734B2 (ja) * 1993-07-28 2002-09-03 ダイアタイド・インコーポレイテッド 放射性同位体標識したグルカン類
US5919466A (en) * 1993-10-01 1999-07-06 Gerbu Biotechnik Gmbh Method for improving the yield of immunoantibodies in the vaccination of animals and humans
AUPM572294A0 (en) * 1994-05-18 1994-06-09 Vaccine Technologies Pty. Ltd. Delivery vehicle for bioactive molecule
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
US5576015A (en) * 1995-03-02 1996-11-19 Donzis; Byron A. Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
JP2001523216A (ja) * 1995-06-26 2001-11-20 リサーチ．トライアングル．ファーマシューティカルズ 新規のアジュバント組成物と、それからなるワクチン製剤
US20080286228A1 (en) * 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
AU703120B2 (en) * 1995-10-20 1999-03-18 University Of Nebraska Board Of Regents Composition and methods for enhancing immune responses mediated by antigen-presenting cells
US6084092A (en) * 1997-01-31 2000-07-04 The Collaborative Group, Ltd. β(1-3)-glucan diagnostic assays
US6110692A (en) 1996-05-01 2000-08-29 The Collaborative Group, Ltd. Receptor for underivatized aqueous soluble β(1-3)-glucan
JPH10139670A (ja) * 1996-11-11 1998-05-26 Terukuni Yakida インターロイキン１２誘導物質及び医薬組成物
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6413715B2 (en) 1997-01-31 2002-07-02 The Collaborative Group β(1-3)-glucan diagnostic assays
US5786343A (en) * 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
DE19737481A1 (de) * 1997-08-28 1999-03-04 Hoechst Ag Sphärische lineare Polysaccharide enthaltende Mikropartikel
KR100680014B1 (ko) * 1997-10-03 2007-02-09 갈레니카 파마슈티칼스 인크. 이민 형성 폴리사카라이드, 이의 제조 방법 및 이것의 아쥬반트 및 면역자극제로서의 용도
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
WO1999030691A2 (en) * 1997-12-18 1999-06-24 Ato B.V. Composition for the controlled release of active compounds
WO1999055715A2 (en) 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
WO2000014547A1 (en) * 1998-09-04 2000-03-16 Powderject Research Limited Immunodiagnostics using particle delivery methods
DE69940371D1 (de) * 1998-09-14 2009-03-19 Nabi Biopharmaceuticals Rockvi Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
US7030101B2 (en) 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
AU6261999A (en) * 1998-09-25 2000-04-17 Collaborative Group, Ltd., The Very high molecular weight beta-glucans
US6369216B1 (en) 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
US6541678B2 (en) * 1999-09-27 2003-04-01 Brennen Medical, Inc. Immunostimulating coating for surgical devices
US20020009463A1 (en) * 2000-02-23 2002-01-24 Jan Raa Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2002058711A1 (en) 2001-01-16 2002-08-01 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
PT1372708E (pt) 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
KR20040039195A (ko) * 2001-04-27 2004-05-10 아지노모토 가부시키가이샤 면역강화제
NO20014256D0 (no) 2001-09-03 2001-09-03 Bjoern Kristiansen Fremstilling av immunstimulerende forbindelse
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
CA2467378C (en) 2001-12-11 2009-09-01 Ceapro Inc. Cereal beta glucan compositions, methods of preparation and uses thereof
AU2003257007A1 (en) * 2002-08-01 2004-02-23 Immusonic, Inc. Beta-glucan containing composites, methods for manufacturing and for using such composites
EP1545208A4 (de) * 2002-08-13 2006-04-12 Biopolymer Engineering Inc Verfahren zur verwendung von beta-glucan als strahlenschutzmittel
AU2003268486A1 (en) * 2002-09-04 2004-03-29 Biopolymer Engineering, Inc. Cancer therapy using whole glucan particles and antibodies
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050281875A1 (en) * 2003-12-17 2005-12-22 Sovereign Pharmaceuticals, Ltd. Promethazine containing dosage form
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20050232987A1 (en) * 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug
US20060029664A1 (en) * 2004-08-04 2006-02-09 Sovereign Pharmaceuticals, Ltd. Dosage form containing carbetapentane and another drug
US20050232986A1 (en) * 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
AU2005207622B2 (en) 2004-01-23 2010-10-28 Eden Research Plc Methods of killing nematodes comprising the application of a terpene component
US20050208145A1 (en) * 2004-03-19 2005-09-22 Thava Vasanthan Grain fiber compositions and methods of use
US20050220846A1 (en) 2004-04-05 2005-10-06 Puntenney Steven B Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function
PL2338332T3 (pl) 2004-05-20 2014-07-31 Eden Research Plc Cząsteczka glukanu kapilarnego lub cząsteczka ściany komórkowej zamykająca składnik terpenowy
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US7514085B2 (en) * 2004-07-16 2009-04-07 Medimush A/S Immune modulating compounds from fungi
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
ES2375995T3 (es) * 2004-09-17 2012-03-08 University Of Massachusetts Composiciones y sus usos para deficiencias de enzima lisosomal.
CN101184780B (zh) 2005-05-05 2012-10-03 森馨香料公司 β-葡聚糖和甘露聚糖的制备
US20090005340A1 (en) * 2005-06-15 2009-01-01 Medimush A/S Bioactive Agents Produced By Submerged Cultivation of a Basidiomycete Cell
WO2006133707A2 (en) 2005-06-15 2006-12-21 Medimush A/S Anti-cancer combination treatment and kit-of-part
EP1948245B1 (de) * 2005-10-24 2011-10-05 University of Massachusetts Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
MX2008006927A (es) * 2005-11-30 2008-10-24 Eden Research Plc Composiciones que contienen terpenos y metodos para hacer y usar los mismos.
US9439416B2 (en) 2005-11-30 2016-09-13 Eden Research Plc Compositions and methods comprising terpenes or terpene mixtures selected from thymol, eugenol, geraniol, citral, and l-carvone
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
WO2007109564A2 (en) * 2006-03-17 2007-09-27 University Of Massachusetts Yeast cell particles as oral delivery vehicles for antigens
WO2007146440A2 (en) * 2006-06-15 2007-12-21 Biopolymer Engineering, Inc. Dba Biothera, Inc. Glucan preparations
US20080167268A1 (en) * 2006-09-01 2008-07-10 Jun Yan Particulate beta-glucan compositions for regulating dendritic cells
WO2008027581A1 (en) * 2006-09-01 2008-03-06 University Of Louisville Mcrp antagonists and their uses
US20090022799A1 (en) * 2006-10-06 2009-01-22 Shikha Pramanik Barman Compositions that contain beta-glucan to be used for the prevention and treatment of disease and methods for their use
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
JP6082174B2 (ja) * 2006-11-06 2017-02-15 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 免疫調節組成物及びその使用方法
EP2222283A2 (de) * 2007-10-29 2010-09-01 University of Massachusetts Zur freisetzung von nukleinsäuren (sirna) mit hefe-zellwandproteinen verkapselte mehrlagige nanopatikel
EP2262538B1 (de) 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-aminosäure konjugate
WO2009114153A1 (en) 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-foscarnet conjugates
US20110059921A1 (en) * 2008-03-27 2011-03-10 Ektar Therapeutics Oligomer-Nitrogenous Base Conjugates
EP2105145A1 (de) * 2008-03-27 2009-09-30 ETH Zürich Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
CN101998866A (zh) * 2008-04-11 2011-03-30 尼克塔治疗公司 低聚物-芳氧基-取代的丙胺共轭物
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
WO2010014258A2 (en) * 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
US8637466B2 (en) 2008-08-11 2014-01-28 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
US9089610B2 (en) * 2008-08-19 2015-07-28 Nektar Therapeutics Complexes of small-interfering nucleic acids
EP3208337A1 (de) 2008-09-02 2017-08-23 Alnylam Pharmaceuticals, Inc. Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
US20110237524A1 (en) * 2008-09-19 2011-09-29 Nektar Therapeutics Polymer conjugates of aod-like peptides
WO2010033216A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of nesiritide peptides
US20110171166A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
EP2334337A1 (de) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymerkonjugate von opioid-wachstumsfaktor-peptiden
WO2010033205A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of v681-like peptides
EP2340047A1 (de) * 2008-09-19 2011-07-06 Nektar Therapeutics Polymerkonjugate von kiss1-peptiden
EP2337585A1 (de) * 2008-09-19 2011-06-29 Nektar Therapeutics Polymerkonjugate von glp-2-artigen peptiden
US20110171162A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
US20110165112A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of c-peptides
EP2898900B1 (de) 2008-09-19 2017-11-15 Nektar Therapeutics Polymerkonjugate von Ziconotid
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2010099200A1 (en) 2009-02-24 2010-09-02 Nektar Therapeutics Oligomer-amino acid conjugates
WO2010099341A1 (en) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mig-12 gene
US8816077B2 (en) 2009-04-17 2014-08-26 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
CA2760706C (en) 2009-05-05 2019-08-06 Alnylam Pharmaceuticals, Inc. Methods of delivering oligonucleotides to immune cells
JP5656980B2 (ja) 2009-05-13 2015-01-21 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー含有の置換芳香族トリアジン化合物
US8785661B2 (en) 2009-05-13 2014-07-22 Nektar Therapeutics Oligome-containing pyrrolidine compounds
US8916693B2 (en) 2009-09-17 2014-12-23 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
WO2011061144A2 (en) 2009-11-20 2011-05-26 Basf Se The present invention relates to the use of beta-(1, 3)- beta-(1, 4) glucan with an average molecular weight of from 5.000 to 150.000 da for the increase of synthesis of collagen
CZ302789B6 (cs) * 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
KR101605932B1 (ko) 2009-12-18 2016-03-24 노파르티스 아게 Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물
US9226970B2 (en) 2010-02-22 2016-01-05 Nektar Therapeutics Oligomer modified diaromatic substituted compounds
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
BR112012024049A2 (pt) 2010-03-24 2017-03-01 Rxi Pharmaceuticals Corp interferência de rna em indicações dérmicas e fibróticas
AU2011237630B2 (en) 2010-04-06 2016-01-21 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of CD274/PD-L1 gene
CN107929306B (zh) 2010-04-23 2022-11-15 箭头制药公司 治疗β-ENaC-相关疾病的有机组合物
US20110293784A1 (en) 2010-05-28 2011-12-01 Anja Wittke Milk-based nutritional compositions
US9944671B2 (en) 2010-06-02 2018-04-17 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
WO2012024229A1 (en) 2010-08-14 2012-02-23 University Of Massachusetts Yeast cell wall particle for receptor-targeted nanoparticle delivery
EP2627639B1 (de) 2010-10-15 2021-12-22 Nektar Therapeutics N-optional substituierte aryl-2-oligomer-3-alkoxypropionamides
EP2648763A4 (de) 2010-12-10 2014-05-14 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
US9193973B2 (en) 2010-12-10 2015-11-24 Alynylam Pharmaceuticals, Inc. Compositions and methods for increasing erythropoietin (EPO) production
WO2012082995A1 (en) 2010-12-15 2012-06-21 Nektar Therapeutics Oligomer-containing hydantoin compounds
WO2012083153A1 (en) 2010-12-16 2012-06-21 Nektar Therapeutics Oligomer-containing apremilast moiety compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130338216A1 (en) 2010-12-22 2013-12-19 Nektar Therapeutics Deuterated and/or fluorinated taxane derivatives
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088506A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-semaxanib moiety conjugates
WO2012088529A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-sunitinib conjugates
US10220020B2 (en) 2010-12-23 2019-03-05 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
MX360349B (es) 2011-03-29 2018-10-30 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
EP2723865B1 (de) 2011-06-21 2019-03-27 Alnylam Pharmaceuticals, Inc. VERFAHREN ZUR BESTIMMUNG DER AKTIVITÄT VON RNAi IN EINEM PATIENTEN
EP3444348A1 (de) 2011-06-21 2019-02-20 Alnylam Pharmaceuticals, Inc. Angiopoietin-3 (angptl3)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2012178033A2 (en) 2011-06-23 2012-12-27 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
WO2013019857A2 (en) 2011-08-01 2013-02-07 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
CN103930547A (zh) 2011-09-02 2014-07-16 诺华股份有限公司 用于治疗hsf1相关疾病的有机组合物
EP2802658A2 (de) 2012-01-09 2014-11-19 Novartis AG Rnai-wirkstoffe zur behandlung von erkrankungen im zusammenhang mit beta-catenin
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
PL2849736T3 (pl) 2012-07-05 2019-06-28 Nutramax Laboratories, Inc. Kompozycje zawierające prekursor sulforafanu glukorafaninę, glukozydazę, kwas askorbinowy i ekstrakt lub proszek z ostropestu plamistego
US20140065173A1 (en) 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
US9375486B2 (en) 2012-09-17 2016-06-28 Nektar Therapeutics Oligomer-containing benzamide-based compounds
GB201220940D0 (en) 2012-11-21 2013-01-02 Eden Research Plc Method P
WO2014093454A1 (en) 2012-12-12 2014-06-19 Orbis Health Solutions, Llc Compositions and methods for tissue regeneration
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
ME03043B (de) 2013-03-14 2018-10-20 Alnylam Pharmaceuticals Inc Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
TW201515650A (zh) 2013-05-06 2015-05-01 艾爾妮蘭製藥公司 遞送經脂質調配之核酸分子之劑量及方法
CA2925107A1 (en) 2013-10-02 2015-04-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
SG11201602631XA (en) 2013-10-04 2016-05-30 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of the alas1 gene
EP3056208B1 (de) * 2013-10-09 2021-08-18 Toray Industries, Inc. Immunpotentiator
EP3071031A1 (de) 2013-11-21 2016-09-28 Eden Research Plc Pestizidzusammensetzung
CA2932753A1 (en) 2013-12-04 2015-06-11 Rxi Pharmaceuticals Corporation Methods for treatment of wound healing utilizing chemically modified oligonucleotides
WO2015092819A2 (en) 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
AU2015217301A1 (en) 2014-02-11 2016-08-25 Alnylam Pharmaceuticals, Inc. Ketohexokinase (KHK) iRNA compositions and methods of use thereof
DK3110437T3 (en) 2014-02-12 2018-01-22 Omnigen Res Llc COMPOSITION AND PROCEDURE FOR PROMOTING REDUCTION OF HEAT Stress FOR ANIMALS
CN106456532B (zh) 2014-03-05 2020-07-24 奥比思健康解决方案有限责任公司 使用酵母细胞壁颗粒的疫苗递送系统
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
WO2015168605A1 (en) 2014-05-01 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
WO2015175510A1 (en) 2014-05-12 2015-11-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a serpinc1-associated disorder
BR122020023687B1 (pt) 2014-05-22 2023-03-07 Alnylam Pharmaceuticals, Inc Agente de ácido ribonucleico (rnai) de fita dupla, seus usos e composição farmacêutica
WO2016007876A1 (en) 2014-07-10 2016-01-14 Biothera, Inc. Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
WO2016038550A1 (en) 2014-09-11 2016-03-17 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
EP3191591A1 (de) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
EP3207138B1 (de) 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
EP3904519A1 (de) 2014-10-30 2021-11-03 Genzyme Corporation Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
WO2016073763A2 (en) 2014-11-06 2016-05-12 Biothera, Inc. Beta-glucan methods and compositions that affect the tumor microenvironment
WO2016089883A1 (en) 2014-12-01 2016-06-09 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
WO2016089433A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
EP3234141A4 (de) 2014-12-18 2018-06-20 Alnylam Pharmaceuticals, Inc. Reversir-tm-verbindungen
KR102888521B1 (ko) 2015-04-06 2025-11-19 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
EP3302525A2 (de) 2015-06-05 2018-04-11 Novartis AG Verfahren und zusammensetzungen zur diagnose, behandlung und überwachung der behandlung von shank3-mangelbedingten erkrankungen
WO2016201301A1 (en) 2015-06-12 2016-12-15 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
EP3310918B1 (de) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Gegen hydroxysäureoxidase (glycolat-oxidase, hao1) gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
US11001845B2 (en) 2015-07-06 2021-05-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US10494632B2 (en) 2015-07-10 2019-12-03 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
CN107922949A (zh) 2015-08-31 2018-04-17 安捷伦科技有限公司 用于通过同源重组的基于crispr/cas的基因组编辑的化合物和方法
CN108368507B (zh) 2015-09-02 2022-03-22 阿尔尼拉姆医药品有限公司 程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
CN120937999A (zh) 2015-09-09 2025-11-14 奥姆尼根研究有限责任公司 颗粒组合物在制备用于施用于水生动物的组合物和/或组合中的用途
CN109563509B (zh) 2015-10-19 2022-08-09 菲奥医药公司 靶向长非编码rna的减小尺寸的自递送核酸化合物
SG11201804729RA (en) 2015-12-07 2018-07-30 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
WO2017214518A1 (en) 2016-06-10 2017-12-14 Alnylam Pharmaceuticals, Inc. COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
EP3484450A4 (de) * 2016-07-18 2020-04-01 Tissuegen, Inc. Verfahren und zusammensetzungen zur aufrechterhaltung der konformation und strukturellen integrität von biomolekülen
US20180245065A1 (en) 2016-11-01 2018-08-30 Novartis Ag Methods and compositions for enhancing gene editing
IL267929B2 (en) 2017-01-10 2023-03-01 Nektar Therapeutics Multi-armed polymer conjugates of tlr agonistic compounds and related immunotherapeutic methods
US11266144B2 (en) 2017-01-10 2022-03-08 Conopco, Inc. Biofilm targeting microcapsule carrying a non-volatile functional material
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
CN110582300B (zh) 2017-05-02 2024-08-02 尼克塔治疗公司 肿瘤免疫治疗性治疗方法
JP2020530442A (ja) 2017-07-10 2020-10-22 ジェンザイム・コーポレーション 血友病を有する対象の出血事象を処置するための方法および組成物
CA3069868A1 (en) 2017-07-13 2019-01-17 Alnylam Pharmaceuticals Inc. Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
WO2019016772A2 (en) 2017-07-21 2019-01-24 Novartis Ag COMPOSITIONS AND METHODS FOR TREATING CANCER
AU2018316694B2 (en) 2017-08-17 2025-07-10 Nektar Therapeutics Immunotherapeutic tumor treatment method
US20200339987A1 (en) 2017-11-09 2020-10-29 Alnylam Pharmaceuticals, Inc. Assays and methods for determining expression of the lect2 gene
WO2019094962A2 (en) * 2017-11-13 2019-05-16 The Regents Of The University Of California Antimicrobial particles and sanitization methods
US10835581B2 (en) 2017-11-28 2020-11-17 University of Pittsburgh—of the Commonwealth System of Higher Education Method of treating insulin resistance
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
GB201800417D0 (en) * 2018-01-11 2018-02-28 Whelan Adam Owen Immunogenic agent and associated compositions, uses and methods
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
WO2019165212A1 (en) 2018-02-22 2019-08-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education TARGETING CANCER-ASSOCIATED LONG NON-CODING RNAs
CN110237249A (zh) * 2018-03-09 2019-09-17 南开大学 特异靶向树突状细胞的新型铝佐剂及在疫苗制备上的应用
US20210023017A1 (en) * 2018-03-16 2021-01-28 University Of Massachusetts Yeast cell wall particle encapsulation of biodegradable pro-payloads
WO2019213276A1 (en) 2018-05-02 2019-11-07 Novartis Ag Regulators of human pluripotent stem cells and uses thereof
US11987792B2 (en) 2018-08-16 2024-05-21 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the LECT2 gene
WO2020060986A1 (en) 2018-09-18 2020-03-26 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk) irna compositions and methods of use thereof
US10913951B2 (en) 2018-10-31 2021-02-09 University of Pittsburgh—of the Commonwealth System of Higher Education Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
LT4285929T (lt) 2018-12-20 2026-01-12 Humabs Biomed Sa Kompleksinė hbv terapija
NO346800B1 (en) 2019-06-28 2023-01-16 Ederagen As Deconstructed soil composition
US20220290152A1 (en) 2019-09-03 2022-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
WO2021067747A1 (en) 2019-10-04 2021-04-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing ugt1a1 gene expression
WO2021087325A1 (en) 2019-11-01 2021-05-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
CA3160657A1 (en) 2019-11-08 2021-05-14 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
MX2022009763A (es) 2020-02-10 2022-09-09 Alnylam Pharmaceuticals Inc Composiciones y metodos para silenciar la expresion del factor de crecimiento endotelial vascular a (vegf-a).
US20230092615A1 (en) 2020-02-21 2023-03-23 Mitotherapeutix Llc Compositions and methods for inhibiting expressing of methylation-controlled j-protein (mcj)
EP4127171A2 (de) 2020-03-30 2023-02-08 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
CA3179411A1 (en) 2020-04-06 2021-10-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing myoc expression
IL297130A (en) 2020-04-07 2022-12-01 Alnylam Pharmaceuticals Inc Compositions and methods for silencing scn9a expression
EP4153746A1 (de) 2020-05-21 2023-03-29 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
US20230203496A1 (en) 2020-06-09 2023-06-29 Alnylam Pharmaceuticals, Inc. Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
AR122722A1 (es) 2020-06-24 2022-09-28 Vir Biotechnology Inc Anticuerpos que neutralizan el virus de la hepatitis b y sus usos
JPWO2022045371A1 (de) * 2020-08-31 2022-03-03
MX2024002440A (es) 2021-08-31 2024-03-08 Alnylam Pharmaceuticals Inc Composiciones de acido ribonucleico de interferencia (arni) del efector b similar al factor de fragmentacion de adn subunidad alfa (dffa) que induce la muerte celular (cideb) y metodos de uso de estas.
WO2023039586A1 (en) 2021-09-10 2023-03-16 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
WO2023088227A1 (zh) 2021-11-16 2023-05-25 上海舶望制药有限公司 抑制血管紧张素原(agt)蛋白表达的组合物和方法
CA3235672A1 (en) 2021-11-29 2023-06-01 Shanghai Argo Biopharmaceutical Co., Ltd. Compositions and methods for inhibiting expression of hepatitis b virus (hbv) protein
TW202345865A (zh) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
CN115317601B (zh) * 2022-04-13 2026-02-27 暨南大学 一种新冠疫苗载体及其应用
TW202424193A (zh) 2022-09-15 2024-06-16 美商艾拉倫製藥股份有限公司 第１３型１７β－羥基類固醇去氫酶（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物及其使用方法
AU2024217843A1 (en) 2023-02-09 2025-07-31 Alnylam Pharmaceuticals, Inc. Reversir molecules and methods of use thereof
WO2025128622A1 (en) 2023-12-12 2025-06-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating transthyretin (ttr)- associated diseases
WO2025128632A1 (en) 2023-12-12 2025-06-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating ketohexokinase (khk)-associated diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2447193A1 (fr) * 1979-01-25 1980-08-22 Unicler Utilisation de pichia ou d'extraits de pichia, comme medicament.
JPS59148726A (ja) * 1983-02-09 1984-08-25 Rooto Seiyaku Kk 徐放性製剤用賦形剤
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US4857505A (en) * 1987-03-09 1989-08-15 American Cyanamid Company Sustained release compositions for parenteral administration and their use

Also Published As

Publication number Publication date
AU5933190A (en) 1991-01-08
US5607677A (en) 1997-03-04
EP0476063B1 (de) 1994-05-25
CA2059275A1 (en) 1990-12-16
WO1990015596A1 (en) 1990-12-27
US5741495A (en) 1998-04-21
ES2053198T3 (es) 1994-07-16
EP0476063A1 (de) 1992-03-25
DE69009185D1 (de) 1994-06-30
JPH05503285A (ja) 1993-06-03
DE69009185T2 (de) 1994-10-27
US5032401A (en) 1991-07-16

Similar Documents

Publication Publication Date Title
DE69009185D1 (de) Arzneimittelfreisetzungssystem aus glucan und adjuvant.
TR199802305T2 (xx) Yanaktan uygulama y�ntemi.
EP0594607A4 (de) Erhöhung der verminderungsregulation von autoimmunkrankheiten durch orale verabreichung von autoantigenen.
ES2172239T3 (es) Sistema osmotico de liberacion de farmacos.
IL134212A0 (en) Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment
DK0663815T3 (da) Inhalationspulvere og fremgangsmåde til fremstilling heraf
JPS57212114A (en) Capsule containing allergen activator and preparation therefor
HU9502063D0 (en) Application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes
EP0652770A4 (de) Orale gabe von antigenen.
NL300330I2 (nl) Preparaat voor het afgeven van peptiden
RU94045825A (ru) Применение материала, полученного из mycobacterium vaccae для производства терапевтического средства для лечения психических заболеваний, способ лечения психических заболеваний, продукт, содержащий антигенный и/или иммунорегуляторный материал, фармацевтическое средство
ATE179333T1 (de) Immunotherapeutische zubereitung
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
DE69812100D1 (de) Adenosin enthaltendes arzneimittel
ATE118351T1 (de) Wirkung von hormonen.
ES2054744T3 (es) Preparaciones percutaneas de liberacion sostenida.
RU94002476A (ru) Лекарственное средство
EP0282343A3 (de) Verfahren zur Stimulierung der Immunreponsibilität zu bestimmten Antigenen
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
FR2662942B1 (fr) Medicament immunostimulant a base de glycopeptidolipides polaires de mycobacterium chelonae.
IL105498A0 (en) Pharmaceutical composition containing ribonucleotide polymerase
CY1106702T1 (el) Χρηση ενος συνδυασμου μιας πουρινης και ενος παραγοντα δοτη μονοξειδιου του αζωτου για την προληψη ή την αγωγη γενετησιων δυσλειτουργιων
DE69429521D1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
DE69323191D1 (de) Wasserlösliche retinoide
ATE87482T1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties